Stayble Therapeutics AB (OSTO:STABL) Short Interest


OSTO:STABL Stayble Therapeutics AB OSTO:STABL
28 GF Score
Price kr0.21
! 1 Warning Sign
View Full Analysis

What is Stayble Therapeutics AB Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

OSTO:STABL vs VRTX, REGN, ALNY: Short Interest Comparison

For the Biotechnology subindustry, Stayble Therapeutics AB's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Stayble Therapeutics AB Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Stayble Therapeutics AB's Short Interest distribution charts can be found below:

* The bar in red indicates where Stayble Therapeutics AB's Short Interest falls into.


OSTO:STABL
28GF Score
Stayble Therapeutics AB OSTO:STABL
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Stayble Therapeutics AB Business Description

Other Exchanges 4K4:Germany
Address Lennart Torstenssonsgatan 6, Gothenburg, SWE, 412 56
Stayble Therapeutics AB is a clinical-stage pharmaceutical company developing STA363, an intradiscally injected formulation against chronic discogenic low back pain. The treatment is aimed at patients whose back pain persists after physiotherapy and analgesics. The injection is given once and the effect is expected to remain throughout the patient's life and requires minimal rehabilitation. The company's injection treatment, STA363, is expected to correct the underlying cause of disc-related low back pain by affecting the two main causative factors namely instability of the disc and prevention of leakage of inflammatory mediators from the disc center.
28GF Score

Get the complete analysis for OSTO:STABL

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.21
Price